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Abstract
Context: Prediction models are developed to aid health care providers in estimating the
probability or risk that a specific disease or condition is present (diagnostic models) or that a
specific event will occur in the future (prognostic models), to inform their decision making.
However, the overwhelming evidence shows that the quality of reporting of prediction model
studies is poor. Only with full and clear reporting of information on all aspects of a prediction
model can risk of bias and potential usefulness of prediction models be adequately assessed.
Objective: The Transparent Reporting of a multivariable prediction model for Individual
Prognosis Or Diagnosis (TRIPOD) Initiative developed a set of recommendations for the
reporting of studies developing, validating, or updating a prediction model, whether for
diagnostic or prognostic purposes.
Evidence acquisition: This article describes how the TRIPOD Statement was developed. An
extensive list of items based on a review of the literature was created, which was reduced
after a Web-based survey and revised during a 3-day meeting in June 2011 with methodol-
ogists, health care professionals, and journal editors. The list was reﬁned during several
meetings of the steering group and in e-mail discussions with the wider group of TRIPOD
contributors.
Evidence synthesis: The resulting TRIPOD Statement is a checklist of 22 items, deemed
essential for transparent reporting of a prediction model study. The TRIPOD Statement aims
to improve the transparency of the reporting of a prediction model study regardless of the
study methods used. The TRIPOD Statement is best used in conjunction with the TRIPOD
explanation and elaboration document.
Conclusions: To aid the editorial process and readers of prediction model studies, it is
recommended that authors include a completed checklist in their submission (also available
at www.tripod-statement.org).
Patient summary: The Transparent Reporting of a multivariable prediction model for
Individual Prognosis Or Diagnosis (TRIPOD) Initiative developed a set of recommendations
for the reporting of studies developing, validating, or updating a prediction model, whether
for diagnostic or prognostic purposes.
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In medicine, patients with their care providers are
confronted with making numerous decisions on the basis
of an estimated risk or probability that a specific disease or
condition is present (diagnostic setting) or a specific event
will occur in the future (prognostic setting) (Fig. 1). In the
diagnostic setting, the probability that a particular disease
is present can be used, for example, to inform the referral of
patients for further testing, initiate treatment directly, or
reassure patients that a serious cause for their symptoms is
unlikely. In the prognostic setting, predictions can be used
for planning lifestyle or therapeutic decisions based on the
risk for developing a particular outcome or state of health
within a specific period [1,2]. Such estimates of risk can also
be used to risk-stratify participants in therapeutic clinical
trials [3,4].
In both the diagnostic and prognostic setting, estimates
of probabilities are rarely based on a single predictor
[5]. Doctors naturally integrate several patient character-
istics and symptoms (predictors, test results) to make a
prediction (see Fig. 2 for differences in common terminol-
ogy between diagnostic and prognostic studies). Predic-
tion is therefore inherently multivariable. Prediction
models (also commonly called ‘‘prognostic models,’’ ‘‘risk
scores,’’ or ‘‘prediction rules’’ [6]) are tools that combine
multiple predictors by assigning relative weights to each
predictor to obtain a risk or probability [1,2]. Well-known[(Fig._1)TD$FIG]
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Fig. 1 – Schematic representation of diagnostic and prognostic prediction mod
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1.1. Prediction model studies
Prediction model studies can be broadly categorized as
model development [12], model validation (with or without
updating) [13] or a combination of both (Fig. 3). Model
development studies aim to derive a prediction model by
selecting the relevant predictors and combining them
statistically into a multivariable model. Logistic and Cox
regression are most frequently used for short-term
(for example, disease absent vs. present, 30-day mortality)
and long-term (for example, 10-year risk) outcomes,
respectively [12–17]. Studies may also focus on quantifying
the incremental or added predictive value of a specific
predictor (for example, newly discovered) to a prediction
model [18].
Quantifying the predictive ability of a model on the same
data fromwhich the model was developed (often referred to
as apparent performance) will tend to give an optimistic
estimate of performance, owing to overfitting (too few
outcome events relative to the number of candidate
predictors) and the use of predictor selection strategies
[19]. Studies developing new prediction models should
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nce a specific event or outcome within a certain time period. In other
ationship, whereas prognostic prediction involves a longitudinal
s, a time window between predictor (index test) measurement and the
as possible and without starting any treatment within this period.
[(Fig._2)TD$FIG]
Despite the diﬀerent nature (timing) of the prediction, there are many similarities between diagnostic and prognostic prediction models, including:
Type of outcome is often binary: either disease of interest present versus absent (in diagnosis) or the future occurrence of an event yes or no (in
prognosis). 
The key interest is to generate the probability of the outcome being present or occurring for an individual, given the values  of 2 or more predictors, with
the purpose of informing patients and guiding clinical decision making.
The same challenges as when developing a multivariable prediction model, such as selection of the predictors, model-building strategies, and handling of  
continuous predictors and the danger of overﬁtting.
The same measures for assessing model performance.
Different terms for similar features between diagnostic and prognostic modeling studies are summarized below.
Diagnostic Prediction Modeling Study
Diagnostic tests or index tests
Target disease/disorder (presence vs. absence)
Reference standard and disease veriﬁcation
Partial veriﬁcation
Explanatory variables, predictors, covariates (X variables)
Outcome (Y variable)
Missing outcomes
Prognostic Prediction Modeling Study
Prognostic factors or indicators
Event (future occurrence: yes or no)
Event deﬁnition and event measurement
Loss to follow-up and censoring
Fig. 2 – Similarities and differences between diagnostic and prognostic prediction models.
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example, calibration and discrimination) of the developed
model. Internal validation techniques use only the original
study sample and include such methods as bootstrapping or
cross-validation. Internal validation is a necessary part of
model development [2]. Overfitting, optimism, and miscali-
bration may also be addressed and accounted for during the
model development by applying shrinkage (for example,
heuristic or based on bootstrapping techniques) or penaliza-
tion procedures (for example, ridge regression or lasso) [20].
After developing a prediction model, it is strongly
recommended to evaluate the performance of the model
in other participant data than was used for the model
development. Such external validation requires that for
each individual in the newdata set, outcome predictions are
made using the original model (that is, the published
regression formula) and compared with the observed
outcomes [13,14]. External validation may use participant
data collected by the same investigators, typically using the
same predictor and outcome definitions and measure-
ments, but sampled from a later period (temporal or narrow
validation); by other investigators in another hospital or
country, sometimes using different definitions and mea-
surements (geographic or broad validation); in similar
participants but from an intentionally different setting
(for example, model developed in secondary care and
assessed in similar participants but selected from primary
care); or even in other types of participants (for example,
model developed in adults and assessed in children, or
developed for predicting fatal events and assessed for
predicting nonfatal events) [13,15,17,21,22]. In case of poor
performance, the model can be updated or adjusted on the
basis of the validation data set [13].1.2. Reporting of multivariable prediction model studies
Studies developing or validating a multivariable prediction
model share specific challenges for researchers [6]. Several
reviews have evaluated the quality of published reports that
describe the development or validation prediction models
[23–28]. For example, Mallett and colleagues [26] examined
47 reports published in 2005 presenting new prediction
models in cancer. Reporting was found to be poor, with
insufficient information described in all aspects of model
development, from descriptions of patient data to statistical
modeling methods. Collins and colleagues [24] evaluated
the methodological conduct and reporting of 39 reports
published before May 2011 describing the development of
models to predict prevalent or incident type 2 diabetes.
Reporting was also found to be generally poor, with key
details on which predictors were examined, the handling
and reporting of missing data, and model-building strategy
often poorly described. Bouwmeester and colleagues [23]
evaluated 71 reports, published in 2008 in 6 high-impact
general medical journals, and likewise observed an
overwhelmingly poor level of reporting. These and other
reviews provide a clear picture that, across different disease
areas and different journals, there is a generally poor level of
reporting of predictionmodel studies [6,23–27,29]. Further-
more, these reviews have shown that serious deficiencies in
the statistical methods, use of small data sets, inappropriate
handling ofmissing data, and lack of validation are common
[6,23–27,29]. Such deficiencies ultimately lead to predic-
tionmodels that are not or should not be used. It is therefore
not surprising, and fortunate, that very few prediction
models, relative to the large number of models published,
are widely implemented or used in clinical practice [6].
[(Fig._3)TD$FIG]
Fig. 3 – Types of prediction model studies covered by the TRIPOD statement.
D = development data; V = validation data.
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years. Health care providers and policy makers are increas-
ingly recommending the use of prediction models within
clinical practice guidelines to inform decision making at
various stages in the clinical pathway [30,31]. It is a general
requirement of reporting of research that other researchers
can, if required, replicate all the steps taken and obtain the
same results [32]. It is therefore essential that key details of
how a prediction model was developed and validated be
clearly reported to enable synthesis and critical appraisal of
all relevant information [14,33–36].
2. Evidence acquisition—Reporting guidelines for
prediction model studies: The TRIPOD Statement
We describe the development of the TRIPOD (Transparent
Reporting of a multivariable prediction model for Individual
Prognosis or Diagnosis) Statement, a guideline specifically
designed for the reportingof studies developingor validatingamultivariable prediction model, whether for diagnostic or
prognostic purposes. TRIPOD is not intended formultivariable
modeling in etiologic studies or for studies investigating single
prognostic factors [37]. Furthermore, TRIPOD is also not
intended for impact studies that quantify the impact of using a
prediction model on participant or doctors’ behavior and
management, participant health outcomes, or cost-effective-
ness of care, compared with not using the model [13,38].
Reporting guidelines for observational (the STrengthen-
ing the Reporting of OBservational studies in Epidemiology
[STROBE]) [39], tumor marker (REporting recommenda-
tions for tumour MARKer prognostic studies [REMARK])
[37], diagnostic accuracy (STAndards for the Reporting of
Diagnostic accuracy studies [STARD]) [40], and genetic risk
prediction (Genetic RIsk Prediction Studies [GRIPS]) [41]
studies all contain many items that are relevant to studies
developing or validating prediction models. However, none
of these guidelines are entirely appropriate for prediction
model studies. The 2 guidelines most closely related to
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focus of the REMARK checklist is primarily on prognostic
factors and not prediction models, whereas the GRIPS
statement is aimed at risk prediction using genetic risk
factors and the specific methodological issues around
handling large numbers of genetic variants.
To address a broader range of studies, we developed the
TRIPOD guideline: Transparent Reporting of a multivariable
prediction model for Individual Prognosis or Diagnosis.
TRIPOD explicitly covers the development and validation of
prediction models for both diagnosis and prognosis, for all
medical domains and all types of predictors. TRIPOD also
places much more emphasis on validation studies and the
reporting requirements for such studies. The reporting of
studies evaluating the incremental value of specific pre-
dictors, beyond established predictors or even beyond
existing prediction models [18,42], also fits entirely within
the remit of TRIPOD (see the accompanying explanation and
elaboration document [43], available at www.annals.org).
3. Evidence synthesis—Developing the TRIPOD
Statement
We convened a 3-day meeting with an international group
of prediction model researchers, including statisticians,
epidemiologists, methodologists, health care professionals,
and journal editors (from Annals of Internal Medicine, BMJ,
Journal of Clinical Epidemiology, and PLoS Medicine) to
develop recommendations for the TRIPOD Statement.
We followed published guidance for developing report-
ing guidelines [44] and established a steering committee
(Drs. Collins, Reitsma, Altman, and Moons) to organize and
coordinate the development of TRIPOD. We conducted a
systematic search of MEDLINE, EMBASE, PsychINFO, and
Web of Science to identify any published articles making
recommendations on reporting of multivariable prediction
models (or aspects of developing or validating a prediction
model), reviews of published reports of multivariable
prediction models that evaluated methodological conduct
or reporting and reviews of methodological conduct and
reporting of multivariable models in general. From these
studies, a list of 129 possible checklist items was generated.
The steering committee thenmerged related items to create
a list of 76 candidate items.
Twenty-five experts with a specific interest in prediction
models were invited by e-mail to participate in the Web-
based survey and to rate the importance of the 76 candidate
checklist items. Respondents (24 of 27) included methodol-
ogists, health care professionals, and journal editors.
(In addition to the 25 meeting participants, the survey was
also completed by 2 statistical editors from Annals of Internal
Medicine.)
The results of the survey were presented at a 3-day
meeting in June 2011, in Oxford, United Kingdom; it was
attended by 24 of the 25 invited participants (22 of whom
had participated in the survey). During the 3-day meeting,
each of the 76 candidate checklist items was discussed in
turn, and a consensus was reached on whether to retain,
merge with another item, or omit the item. Meetingparticipants were also asked to suggest additional items.
After the meeting, the checklist was revised by the steering
committee during numerous face-to-face meetings, and
circulated to the participants to ensure it reflected the
discussions. While making revisions, conscious efforts were
made to harmonize our recommendations with other
reporting guidelines, and where possible we chose the
same or similar wording for items [37,39,41,45,46].
3.1. TRIPOD components
The TRIPOD Statement is a checklist of 22 items that we
consider essential for good reporting of studies developing
or validating multivariable prediction models (Fig. 4). The
items relate to the title and abstract (items 1 and 2),
background and objectives (item 3), methods (items
4 through 12), results (items 13 through 17), discussion
(items 18 through 20), and other information (items 21 and
22). The TRIPOD Statement covers studies that report solely
development [12,15], both development and external
validation, and solely external validation (with or without
updating), of a prediction model [14] (Fig. 3). Therefore,
some items are relevant only for studies reporting the
development of a prediction model (items 10a, 10b, 14, and
15), and others apply only to studies reporting the
(external) validation of a prediction model (items 10c,
10e, 12, 13c, 17, and 19a). All other items are relevant to all
types of prediction model development and validation
studies. Items relevant only to the development of a
predictionmodel are denoted byD, items relating solely to a
validation of a prediction model are denoted by V, whereas
items relating to both types of study are denoted D;V.
The recommendations within TRIPOD are guidelines
only for reporting research and do not prescribe how to
develop or validate a prediction model. Furthermore, the
checklist is not a quality assessment tool to gauge the
quality of a multivariable prediction model.
An ever-increasing number of studies are evaluating the
incremental value of specific predictors, beyond established
predictors or even beyond existing prediction models
[18,42]. The reporting of these studies fits entirely within
the remit of TRIPOD (see accompanying explanation and
elaboration document [43]).
3.2. The TRIPOD explanation and elaboration document
In addition to the TRIPOD Statement, we produced a
supporting explanation and elaboration document [43] in a
similar style to those for other reporting guidelines [47–49].
Each checklist item is explained and accompanied by
examples of good reporting from published articles. In
addition, because many such studies are methodologically
weak, we also summarize the qualities of good (and the
limitations of less good) studies, regardless of reporting
[43]. A comprehensive evidence base from existing system-
atic reviews of prediction models was used to support and
justify the rationale for including and illustrating each
checklist item. The development of the explanation
and elaboration document was completed after several
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the authors. Additional revisionsweremade after sharing the
documentwith thewholeTRIPODgroupbefore finalapproval.
3.3. Role of the funding source
There was no explicit funding for the development of this
checklist and guidance document. The consensus meeting[(Fig._4)TD$FIG]Development Item Section/Topic 
or Validation? 
Title and 
abstract 
Title 1 D;V
Abstract D;V 2 
Introduction 
Background 
and objectives
3a D;V
3b D;V
Methods
Source of 
data
D;V 4a 
D;V 4b 
Participants
5a D;V
5b D;V
5c D;V
Outcome
D;V 6a 
D;V 6b 
Predictors 
7a D;V
7b D;V
D;V 8 Sample size 
Missing data 9 D;V
Statistical
analysis 
methods 
D 10a 
D 10b 
V 10c 
D;V 10d 
V 10e 
Risk groups 11 D;V
Fig. 4 – Checklist of items to include when reporting a study developing or val
Items relevant only to the development of a prediction model are denoted by
by V, and items relating to both are denoted D;V. We recommend using the TR
elaboration document.in June 2011 was partially funded by a National Institute
for Health Research Senior Investigator Award held
by Dr. Altman, Cancer Research UK, and the Netherlands
Organization for Scientific Research. Drs. Collins and
Altman are funded in part by theMedical Research Council.
Dr. Altman is a member of the Medical Research Council
Prognosis Research Strategy (PROGRESS) Partnership. The
funding sources had no role in the study design, dataChecklist Item
Identify the study as developing and/or validating 
a multivariable prediction model, the target 
population, and the outcome to be predicted. 
Provide a summary of objectives, study design, 
setting, participants, sample size, predictors, 
outcome, statistical analysis, results, and 
conclusions.
Explain the medical context (including whether 
diagnostic or prognostic) and rationale for 
developing or validating the multivariable 
prediction model, including references to existing 
models. 
Specify the objectives, including whether the 
study describes the development or validation of 
the model, or both. 
Describe the study design or source of data (e.g., 
randomized trial, cohort, or registry data), 
separately for the development and validation 
data sets, if applicable. 
Specify the key study dates, including start of 
accrual; end of accrual; and, if applicable, end of 
follow-up.  
Specify key elements of the study setting (e.g., 
primary care, secondary care, general 
population) including number and location of 
centres. 
Describe eligibility criteria for participants.  
Give details of treatments received, if relevant.  
Clearly define the outcome that is predicted by 
the prediction model, including how and when 
assessed.
Report any actions to blind assessment of the 
outcome to be predicted.  
Clearly define all predictors used in developing 
the multivariable prediction model, including how 
and when they were measured. 
Report any actions to blind assessment of 
predictors for the outcome and other predictors.  
Explain how the study size was arrived at. 
Describe how missing data were handled (e.g., 
complete-case analysis, single imputation, 
multiple imputation) with details of any imputation 
method.  
Describe how predictors were handled in the 
analyses.  
Specify type of model, all model-building 
procedures (including any predictor selection), 
and method for internal validation. 
For validation, describe how the predictions were 
calculated.  
Specify all measures used to assess model 
performance and, if relevant, to compare multiple 
models.  
Describe any model updating (e.g., recalibration) 
arising from the validation, if done. 
Provide details on how risk groups were created, 
if done.  
idating a multivariable prediction model for diagnosis or prognosis.
D, items relating solely to a validation of a prediction model are denoted
IPOD checklist in conjunction with the TRIPOD explanation and
[(_)TD$FIG]
Development 
vs. validation 
V 12 
For validation, identify any differences from the 
development data in setting, eligibility criteria, 
outcome, and predictors.  
Results
Participants
13a D;V
Describe the flow of participants through the 
study, including the number of participants with 
and without the outcome and, if applicable, a 
summary of the follow-up time. A diagram may be 
helpful.  
13b D;V
Describe the characteristics of the participants 
(basic demographics, clinical features, available 
predictors), including the number of participants 
with missing data for predictors and outcome.  
13c V
For validation, show a comparison with the 
development data of the distribution of important 
variables (demographics, predictors and 
outcome).  
Model 
development 
D 14a 
Specify the number of participants and outcome 
events in each analysis. 
D 14b 
If done, report the unadjusted association 
between each candidate predictor and outcome. 
Model 
specification 
15a D
Present the full prediction model to allow 
predictions for individuals (i.e., all regression 
coefficients, and model intercept or baseline 
survival at a given time point). 
15b D Explain how to use the prediction model. 
Model 
performance 
D;V 16 
Report performance measures (with CIs) for the 
prediction model. 
Model 
updating 
17 V
If done, report the results from any model 
updating (i.e., model specification, model 
performance). 
Discussion 
Limitations D;V 18 
Discuss any limitations of the study (such as 
nonrepresentative sample, few events per 
predictor, missing data).  
Interpretation
19a V
For validation, discuss the results with reference 
to performance in the development data, and any 
other validation data.  
19b D;V
Give an overall interpretation of the results, 
considering objectives, limitations, results from 
similar studies, and other relevant evidence.  
Implications D,V 20 
Discuss the potential clinical use of the model 
and implications for future research.  
Other information 
Supplementary
information 21 D;V
Provide information about the availability of 
supplementary resources, such as study protocol, 
Web calculator, and data sets.  
Funding
D;V 22 
Give the source of funding and the role of the 
funders for the present study.  
Fig. 4. (Continued ).
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decision to submit the manuscript for publication.
4. Discussion
Many reviews have showed that the quality of reporting in
published articles describing the development or validation
of multivariable prediction models in medicine is poor
[23–27,29]. In the absence of detailed and transparent
reporting of the key study details, it is difficult for the
scientific and health care community to objectively judge
the strengths and weaknesses of a prediction model study
[34,50,51]. The explicit aim of this checklist is to improve
the quality of reporting of published prediction model
studies. The TRIPOD guideline has been developed to
support authors in writing reports describing the develop-
ment, validation or updating of prediction models, aideditors and peer reviewers in reviewing manuscripts
submitted for publication, and help readers in critically
appraising published reports.
The TRIPOD Statement does not prescribe how studies
developing, validating, or updating prediction models
should be undertaken, nor should it be used as a tool for
explicitly assessing quality or quantifying risk of bias in such
studies [52]. There is, however, an implicit expectation that
authors have an appropriate study design and conducted
certain analyses to ensure all aspects of model development
and validation are reported. The accompanying explanation
and elaboration document describes aspects of good practice
for such studies, as well as highlighting some inappropriate
approaches that should be avoided [43].
TRIPOD encourages complete and transparent report-
ing reflecting study design and conduct. It is a minimum
set of information that authors should report to inform
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not suggesting a standardized structure of reporting,
rather that authors should ensure that they address all
the checklist items somewhere in their article with
sufficient detail and clarity.
We encourage researchers to develop a study protocol,
especially for model development studies, and even
register their study in registers that accommodate obser-
vational studies (such as ClinicalTrials.gov) [53,54]. The
importance of also publishing protocols for developing or
validating prediction models, certainly when conducting a
prospective study, is slowly being acknowledged [55,56].
Authors can also include the study protocol when submit-
ting their article for peer review, so that readers can know
the rationale for including individuals into the study or
whether all of the analyses were prespecified.
5. Conclusions
Tohelp theeditorialprocess; peer reviewers; and, ultimately,
readers, we recommend submitting the checklist as an
additional file with the report, indicating the pages where
information for each item is reported. The TRIPOD reporting
template for the checklist can be downloaded from www.
tripod-statement.org.
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Editors’ Note
In order to encourage dissemination of the TRIPOD
Statement, this article is freely accessible on the Annals of
Internal Medicine Web site (www.annals.org) and will also
be published in BJOG, British Journal of Cancer, British Journal
of Surgery, BMC Medicine, British Medical Journal, Circulation,
Diabetic Medicine, European Journal of Clinical Investigation,
European Urology, and Journal of Clinical Epidemiology. The
authors jointly hold the copyright of this article. An
accompanying Explanation and Elaboration article is freely
available only on www.annals.org; Annals of Internal
Medicine holds copyright for that article.
Announcements and information relating to TRIPODwill
be broadcast on the TRIPOD Twitter address (@TRI-
PODStatement). The Enhancing the QUAlity and Transpar-
ency Of health Research (EQUATOR) Network (www.
equator-network.org) will help disseminate and promote
the TRIPOD Statement.
E U RO P E AN URO LOG Y 6 7 ( 2 0 1 5 ) 1 1 4 2 – 1 1 5 11150Methodological issues in developing, validating, and
updating prediction models evolve. TRIPOD will be periodi-
cally reappraised, and if necessary modified to reflect
comments, criticisms, and any new evidence. We therefore
encourage readers to make suggestions for future updates
so that ultimately, the quality of prediction model studies
will improve.
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